Multiple competing factors (economic, environmental, social, and personal) influence health outcomes. For many patients, the lack of adequate insurance coverage is an obstacle to timely and appropriate medical care. Cancer survivors may be particularly vulnerable to the ill effects of insufficient insurance benefits. In one recent study comparing cancer survivors with their unaffected siblings, cancer survivors were more likely to lack employer-sponsored coverage, have been denied coverage, have Medicaid, and have high out-of-pocket costs. They were also more likely than their siblings to borrow money for medical expenses, worry that they would not receive a medical procedure, and not fill a prescription.1 Uninsured survivors suffered even greater disparities when compared with insured survivors, and were less likely to have a primary care provider or fill a prescription, and more likely to postpone preventive care.1
Park ER, Kirchhoff AC, Nipp RD et al.. Assessing health insurance coverage characteristics and impact on health care cost, worry, and access: a report from the Childhood Cancer Survivor study [published online ahead of print September 215, 2017]. JAMA Intern Med, doi: 10.1001/jamainternmed.2017.5047.
- Search Google Scholar
- Export Citation
. Park ER Kirchhoff AC Nipp RD Assessing health insurance coverage characteristics and impact on health care cost, worry, and access: a report from the Childhood Cancer Survivor study [published online ahead of print September 215, 2017]. JAMA Intern Med, doi: 10.1001/jamainternmed.2017.5047.
Colorectal Cancer Screening: Insurance Coverage. American Cancer Society Web site. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/screening-coverage-laws.html. Accessed November 16, 2017.
Farkas DT, Greenbaum A, Singhal V, Cosgrove JM. Effect of insurance status on the stage of breast and colorectal cancers in a safety-net hospital. J Oncol Pract 2012;8(3 Suppl):16s–21s.
Adamson AS, Zhou L, Baggett CD et al.. Association of delays in surgery for melanoma with insurance type. JAMA Dermatol 2017;153:1106–1113.
Shi R, Taylor H, McLarty J et al.. Effects of payer status on breast cancer survival: a retrospective study. BMC Cancer 2015;15:211.
Hershman DL, Tsui J, Wright JD et al.. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol 2015;33:1053–1059.
Gradishar WJ, Anderson BO, Balassanian R et al.. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2017. Accessed November 15, 2017. To view the most recent version of these guidelines, visit NCCN.org.
Howell A, Cuzick J, Baum M et al.. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60–62.